Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer
Title: | Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer |
Authors: | Baba, Motoi Browse this author | Takahashi, Masato Browse this author | Yamashiro, Katsushige Browse this author | Yokoo, Hideki Browse this author →KAKEN DB | Fukai, Moto Browse this author →KAKEN DB | Sato, Masanori Browse this author | Hosoda, Mitsuchika Browse this author →KAKEN DB | Kamiyama, Toshiya Browse this author →KAKEN DB | Taketomi, Akinobu Browse this author →KAKEN DB | Yamashita, Hiroko Browse this author →KAKEN DB |
Keywords: | NF-κB/p65 | Triple-negative breast cancer | Prognosis | Neoadjuvant chemotherapy |
Issue Date: | Jul-2016 |
Publisher: | Springer |
Journal Title: | Surgery today |
Volume: | 46 |
Issue: | 7 |
Start Page: | 843 |
End Page: | 851 |
Publisher DOI: | 10.1007/s00595-015-1265-5 |
PMID: | 26494004 |
Abstract: | Purpose: Recent studies have indicated that constitutive NF-κB activity could be involved in the proliferation of triple-negative breast cancer. Methods: NF-κB/p65 expression and the effects of the NF-κB inhibitor, (-)-DHMEQ were examined in triple-negative MDA-MB-231 breast cancer cells. Women with triple-negative breast cancer treated with neoadjuvant chemotherapy between 2002 and 2012 were retrospectively analyzed. Expression of NF-κB/p65, Bcl2 and Ki67 was examined by immunohistochemistry in pre- and post-treatment specimens, and predictive factors for neoadjuvant chemotherapy and prognosis were analyzed. Results: NF-κB/p65 was dominantly expressed in the cytoplasm in MDA-MB-231 cells. Of 34 triple-negative breast cancer patients, positive staining for NF-κB/p65 expression was detected in the nuclei of a few cells in 7 tumors before neoadjuvant chemotherapy, although expression of NF-κB/p65 in the cytoplasm was detected in almost all tumor cells of 33 tumors. Expression levels of NF-κB/p65 were not associated with response to neoaduvant chemotherapy, although expression levels of cytoplasmic NF-κB/p65 intensity were significantly decreased in post-treatment tumor samples compared with those in pretreatment samples. All patients whose tumors showed strong cytoplasmic NF-κB/p65 expression before neoadjuvant chemotherapy are currently disease-free. Conclusion: Our results suggest that strong cytoplasmic NF-κB/p65 expression could be a prognostic marker in triple-negative breast cancer. |
Rights: | The final publication is available at link.springer.com |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/66414 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 山下 啓子
|